In collaboration with the Institute Antiviral Research at Utah State, Gnubiotics has accelerated pre-clinical trials to explore the effects of its multivalent glycan formulations on live SARS-CoV-2 viruses in cell culture as well as evaluating the inhibition of viral induced cytopathic effects (CPE).
Targeting of glycans known to be present on the SARS-CoV-2 cell surface, which have been shown to be critical to viral binding, is a novel approach under consideration for inhibition of SARS-CoV-2 viral entry and adsorption into target host cells.
Early data has shown sialylated glycans may have an effect on a range of virus including the influenza virus. Gnubiotics remains optimistic that we can be part of the global solution and response to stop the COVID-19 pandemic.

Read Press Release